Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: Application in pharmacokinetic drug-drug interaction studies

European Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2011, Pages 225-233

  Yang, Shuying ^a   Beerahee, Misba ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Clinical trial simulation population pharmacokinetic analysis; Drug drug interaction; Power; Sample size

Indexed keywords

METHOTREXATE;

ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; INTERMETHOD COMPARISON; PARALLEL DESIGN; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SAMPLE SIZE; SIMULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; HUMANS; METHOTREXATE; MODELS, BIOLOGICAL; SAMPLE SIZE;

EID: 79954444613     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0957-4     Document Type: Article

References (17)

1. FDA guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis and recommendations for dosing and labelling, November 1999
2. Williams P, Ette NI (2007) Pharmacometrics: Impacting drug development and pharmacotherapy. Pharmacometrics: The science of quantitative pharmacology, edited by Ette EI and Williams P., John Wiley & Sons, Inc. 1
3. FDA Guidance for Industry: Population Pharmacokinetics, February 1999
4. H Zhou 2006 Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J Clin Pharmacol 46 1268 1289 1:CAS:528:DC%2BD28Xht1WjsbzL 10.1177/0091270006294278 17050792 (Pubitemid 44564356)
5. Ogungbenro K, Gueorguieva I, and Aarons L (2007) PopDes V3.0 Manual
6. I Gueorguieva K Ogungbenro G Graham S Glatta L Aarons 2007 A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models Comput Meth Programs Biomed 86 51 61 10.1016/j.cmpb.2007.01.004 (Pubitemid 46394511)
7. C Godfrey K Sweeney K Miller R Hamilton J Kremer 1998 The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis Br J Clin Pharmacol 46 369 376 1:CAS:528:DyaK1cXmvFWntbs%3D 10.1046/j.1365-2125.1998.t01- 1-00790.x 9803986
8. Beal SL, Sheiner LB (eds) (1992) NONMEM users guides, NONMEM Project Group. University of California at San Francisco, San Francisco
9. Beal SL, Sheiner LB and Boeckmann AJ (eds) (1989-2006) NONMEM users guides. Icon development solutions. Ellicott City
10. The R project for statistical computing, http://www.r-project.org
11. Perl-speaks-NONMEM, http://psn.sourceforge.net/
12. Pharsight (1998-2007) WinNonlin professional, version 5.2. Pharsight Corporation
13. PASS 2008, Power analysis and sample size, http://www.ncss.com/download- PASS2.html
14. PJ Marroum RS Uppoor T Parmelee, et al. 2000 In vivo drug-drug interaction studies - a survey of all new molecular entities approved from 1987 to 1997 Clin Pharmacol Ther 68 280 285 1:CAS:528:DC%2BD3cXntFOgtbg%3D 10.1067/mcp.2000.109366 11014409
15. Hu C and Sale M (2007) Population Modeling Approach in Bioequivalence Assessment. Pharmacometrics: The science of quantitative pharmacology, edited by Ette EI and Williams P., John Wiley & Sons, Hoboken Inc. 421.
16. D Kang JB Schwartz D Verotta 2004 A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models Stat Med 23 2551 2566 10.1002/sim.1695 15287084 (Pubitemid 39149267)
17. D Kang JB Schwartz D Verotta 2005 Sample size computations for PK/PD population models J Pharmacokinet Pharmacodyn 32 5-6 685 701 10.1007/s10928-005-0078-3 16284914 (Pubitemid 41772353)